Insmed Stock Surges on Positive Pulmonary Hypertension Trial Results
Insmed's experimental therapy for pulmonary arterial hypertension succeeded in a mid-stage trial, causing shares of competitors Liquidia and United Therapeutics to fall in premarket trading.